For instance: Immunotherapeutic strategies with anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PD-L1) antibodies play a crucial role in the treatment of head and neck SCC (HNSCC), including OSCC [80]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.